ReviewFrontiers in immunology2022
From IL-17 to IFN-γ in inflammatory skin disorders: Is transdifferentiation a potential treatment target?
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis.PloS one · 2023Pooled it
- The Double-Edged Sword of Type 17 Immunity in Wound Healing and Skin Barrier Repair: Microenvironment-Driven Functional Plasticity.Biomolecules · 2026Review
- Fibroblast-derived small extracellular vesicles loaded with tacrolimus enhances dermal delivery and alleviates cytokine-overdriven skin inflammation.Drug delivery and translational research · 2026Article
- Using HLA-DR3-CBA/J Humanized Mice to Develop a Novel Genetic Model for Autoimmune Thyroiditis.Genes · 2026Article
- Bovine natural killer cell subsets can be defined by differential expression of CD161 (Frontiers in immunology · 2026Article
- Enhancement of Psoriasis Treatment by Phellodendri Chinensis Cortex Carbon Dots (PCC-CDs) Through Modulation of the HMGB1/TLR4/MAPK/NF-κB Pathway.International journal of nanomedicine · 2026Article
- Illuminating New Frontiers: Exploring the Photosensitizing Potential of Passiflora Species in Combating Methicillin-Resistant Staphylococcus aureus (MRSA) and Their Infection in Senescent Mice.Advanced biology · 2025Article
- Interferons in Autoimmunity: From Loss of Tolerance to Chronic Inflammation.Biomedicines · 2025Review
- Skin Microbiome, Inflammation, and Skin Toxicities in Women With Breast Cancer Receiving Moderately Hypofractionated Radiation Therapy.International journal of radiation oncology, biology, physics · 2025Article
- Unraveling the role of shrimp hydrolysate as a food supplement in the immune function and fecal microbiota of beagle dogs.Scientific reports · 2025Article
- Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation.Breast cancer research and treatment · 2025Article
- Exploring the influence of gut microbiota metabolites on vitiligo through the gut-skin axis.Frontiers in microbiology · 2025Review
- Immunological Antagonism Between Psoriasis and Atopic Dermatitis: Pathways, Clinical Implications, and Therapeutic Perspectives.Clinical, cosmetic and investigational dermatology · 2025Review
- Immune Dysregulation and Cellular Composition in Lichen Sclerosus Revealed by Integrative Epigenetic Analysis with Cell Type Deconvolution.Journal of inflammation research · 2025Article
- Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications.Journal of clinical medicine · 2024Review
- Natural Product-Derived Compounds Targeting Keratinocytes and Molecular Pathways in Psoriasis Therapeutics.International journal of molecular sciences · 2024Review
- Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003-2022).Heliyon · 2024Article
- Identification of Shared Biomarkers and Immune Infiltration Signatures between Vitiligo and Hashimoto's Thyroiditis.Clinical, cosmetic and investigational dermatology · 2024Article
- Clinical efficacy of COFrontiers in medicine · 2024Article
- Inflammation and Psoriasis: A Comprehensive Review.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The targeted inhibition of effector cytokines such as interleukin 17 (IL-17) in psoriasis and IL-13 in atopic dermatitis offers impressive efficacy with a favorable side effect profile. In contrast, the downregulation of interferon gamma (IFN-γ) in T helper (Th) 1-dominant skin disorders may lead to more adverse events, given the crucial role of IFN-γ in antiviral and antitumoral immunity. Modulating Th17 and Th2 cell differentiation is performed by blocking IL-23 and IL-4, respectively, whereas anti-IL-12 antibodies are only moderately effective in downregulating Th1 lymphocyte differentiation. Therefore, a targeted approach of IFN-γ-driven disorders remains challenging. Recent literature suggests that certain pathogenic Th17 cell subsets with Th1 characteristics, such as CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.